Teva Pharmaceutical Industries Ltd TEVJF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TEVJF is a good fit for your portfolio.
News
-
Teva Closes Collaboration Deal With Sanofi on IBD Treatment
-
Teva shares climb as third-quarter sales top estimates
-
Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri
-
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
-
Teva partnership with Sanofi 'will pay dividends,' analyst says
-
Sanofi, Teva Collaborate on Inflammatory Bowel Disease Drug
-
Alkermes shares surge after settlement with Teva on alcohol dependence treatment
-
Teva Pharmaceuticals agrees to pay $225 million fine to settle price-fixing charges
Trading Information
- Previous Close Price
- $8.67
- Day Range
- $9.40–9.40
- 52-Week Range
- $7.03–10.39
- Bid/Ask
- $4.86 / $15.00
- Market Cap
- $10.54 Bil
- Volume/Avg
- 525 / 381
Key Statistics
- Price/Earnings (Normalized)
- 4.14
- Price/Sales
- 0.69
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Value
- Total Number of Employees
- 35,125
- Website
- https://www.tevapharm.com
Competitors
Valuation
|
Metric
|
TEVJF
|
NVS
|
RDY
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.14 | 14.18 | 17.97 |
Price/Book Value | 1.52 | 5.19 | 3.79 |
Price/Sales | 0.69 | 4.24 | 3.54 |
Price/Cash Flow | 8.05 | 13.40 | 14.05 |
Price/Earnings
TEVJF
NVS
RDY
Financial Strength
|
Metric
|
TEVJF
|
NVS
|
RDY
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.41 | 1.87 |
Current Ratio | 1.00 | 0.94 | 2.59 |
Interest Coverage | −1.16 | 11.35 | 44.72 |
Quick Ratio
TEVJF
NVS
RDY
Profitability
|
Metric
|
TEVJF
|
NVS
|
RDY
|
|---|---|---|---|
Return on Assets (Normalized) | 4.58% | 11.87% | 16.33% |
Return on Equity (Normalized) | 25.82% | 25.88% | 22.82% |
Return on Invested Capital (Normalized) | 9.39% | 17.42% | 21.20% |
Return on Assets
TEVJF
NVS
RDY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Wsklr | $84.8 Bil | |
MKKGY
| Merck KGaA ADR | Mydftz | $66.6 Bil | |
HLN
| Haleon PLC ADR | Krm | $37.8 Bil | |
VTRS
| Viatris Inc | Jwfwm | $11.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zhbkl | $11.5 Bil | |
CTLT
| Catalent Inc | Pgfwpv | $6.7 Bil | |
PRGO
| Perrigo Co PLC | Yscsw | $4.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Trqgv | $3.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Sttjnsz | $3.0 Bil | |
GTBIF
| Green Thumb Industries Inc | Lfcdj | $2.7 Bil |